4.6 Article

Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5

Journal

BMC CANCER
Volume 11, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2407-11-39

Keywords

-

Categories

Funding

  1. Dutch Cancer Society [2000-2286]

Ask authors/readers for more resources

Background: rhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces apoptosis in cancer cells by activating the membrane death receptors 4 and 5 (DR4 and DR5). Here, we investigated each receptor's contribution to rhTRAIL sensitivity and rhTRAIL resistance. We assessed whether agonistic DR4 or DR5 antibodies could be used to circumvent rhTRAIL resistance, alone or in combination with various chemotherapies. Methods: Our study was performed in an isogenic model comprised of the SW948 human colon carcinoma cell line and its rhTRAIL resistant sub-line SW948-TR. Effects of rhTRAIL and agonistic DR4/DR5 antibodies on cell viability were measured using MTT assays and identification of morphological changes characteristic of apoptosis, after acridine orange staining. Sensitivity to the different death receptor ligands was stimulated using pretreatment with the cytokine IFN-gamma and the proteasome inhibitor MG-132. To investigate the mechanisms underlying the changes in rhTRAIL sensitivity, alterations in expression levels of targets of interest were measured by Western blot analysis. Co-immunoprecipitation was used to determine the composition of the death-inducing signalling complex at the cell membrane. Results: SW948 cells were sensitive to all three of the DR-targeting agents tested, although the agonistic DR5 antibody induced only weak caspase 8 cleavage and limited apoptosis. Surprisingly, agonistic DR4 and DR5 antibodies induced equivalent DISC formation and caspase 8 cleavage at the level of their individual receptors, suggesting impairment of further caspase 8 processing upon DR5 stimulation. SW948-TR cells were cross-resistant to all DR-targeting agents as a result of decreased caspase 8 expression levels. Caspase 8 protein expression was restored by MG-132 and IFN-gamma pretreatment, which also re-established sensitivity to rhTRAIL and agonistic DR4 antibody in SW948-TR. Surprisingly, MG-132 but not IFN-gamma could also increase DR5-mediated apoptosis in SW948-TR. Conclusions: These results highlight a critical difference between DR4- and DR5-mediated apoptotic signaling modulation, with possible implications for future combinatorial regimens.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

I. C. Kok, J. S. Hooiveld, P. P. van de Donk, D. Giesen, E. L. van der Veen, M. N. Lub-de Hooge, A. H. Brouwers, T. J. N. Hiltermann, A. J. van der Wekken, L. B. M. Hijmering-Kappelle, W. Timens, S. G. Elias, G. A. P. Hospers, H. J. M. Groen, W. Uyterlinde, B. van der Hiel, J. B. Haanen, D. J. A. de Groot, M. Jalving, E. G. E. de Vries

Summary: The study found that the uptake of Zr-89-pembrolizumab in tumor lesions correlated with treatment response and patient survival. The optimal dose was 5 mg pembrolizumab, and the optimal time point for PET scanning was day 7.

ANNALS OF ONCOLOGY (2022)

Article Oncology

Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Karlijn de Joode, Jolien Tol, Paul Hamberg, Marissa Cloos, Elisabeth A. Kastelijn, Jessica S. W. Borgers, Veerle J. A. A. Nuij, Yarne Klaver, Gerarda J. M. Herder, Pim G. N. J. Mutsaers, Daphne W. Dumoulin, Esther Oomen-de Hoop, Nico G. J. van Diemen, Eduard J. Libourel, Erica J. Geraedts, Gerben P. Bootsma, Cor H. van der Leest, Anne L. Peerdeman, Karin H. Herbschleb, Otto J. Visser, Haiko J. Bloemendal, Hanneke W. M. van Laarhoven, Elisabeth G. E. de Vries, Lizza E. L. Hendriks, Laurens Beerepoot, Hans M. Westgeest, Franchette W. P. J. van den Berkmortel, John B. A. G. Haanen, Anne-Marie C. Dingemans, Astrid A. M. van der Veldt

Summary: This study aimed to investigate the clinical patient characteristics related to COVID-19 outcomes and advanced care planning in cancer patients. The study found that patients with hematological malignancies or lung cancer were at a higher risk of fatal outcomes compared to other solid tumors, and there was no correlation between anticancer therapies and the risk of fatal COVID-19 outcomes. Timely end-of-life communication and early discussion of treatment restrictions should be part of routine oncological care, especially during the COVID-19 pandemic.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally: the Kazakh experience

N. J. Latino, M. Galotti, N. Cherny, E. G. E. de Vries, J-Y Douillard, D. Kaidarova, A. Ilbawi

Summary: The ESMO four-phase approach resulted in updating the Kazakhstan national essential cancer medicines list and cancer treatment protocols, leading to the removal of low-value or non-evidence-based medicines and an increase in budget for cancer care. This approach can improve access to medicines, expenditure efficiency, and sustainability of cancer systems, showcasing how collaboration between WHO and ESMO can positively impact patient care through sharing best practices and resources.

ESMO OPEN (2022)

Article Oncology

Ontario, Canada. 7

Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries

Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.

CLINICAL CANCER RESEARCH (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations

Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard

Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.

MOLECULAR IMAGING AND BIOLOGY (2023)

Review Public, Environmental & Occupational Health

Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward

Kristina Jenei, Zeba Aziz, Christopher Booth, Bernadette Cappello, Francesco Ceppi, Elisabeth G. E. de Vries, Antonio Fojo, Bishal Gyawali, Andre Ilbawi, Dorothy Lombe, Manju Sengar, Richard Sullivan, Dario Trapani, Benedikt D. Huttner, Lorenzo Moja

Summary: The selection of cancer medicines for national procurement requires consideration of various factors, and the WHO has implemented updated processes and selection principles to promote the procurement of high-value essential cancer medicines.

LANCET GLOBAL HEALTH (2022)

Article Medicine, General & Internal

Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

Niccolo Rossi, Karla A. Lee, Maria Bermudez, Alessia Visconti, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Bjork, Laura Kist de Ruijter, Julia Newton-Bishop, Mark Harland, Heather M. Shaw, Mark Harries, Joseph Sacco, Ruth Board, Paul Lorigan, Elisabeth G. E. de Vries, Nicola Segata, Leonie Taams, Sophie Papa, Tim D. Spector, Paul Nathan, Rinse K. Weersma, Geke A. P. Hospers, Rudolf S. N. Fehrmann, Veronique Bataille, Mario Falchi

Summary: This study investigates the potential of circulating inflammatory proteins as biomarkers for immune checkpoint inhibitor therapy in advanced melanoma. The findings suggest that pre-treatment levels of IL-6, HGF, and MCP-2 are associated with treatment response, while on-treatment changes in these proteins are not correlated with response. Inflammatory proteins could serve as predictive biomarkers of ICI response and potential targets for combination therapy.

EBIOMEDICINE (2022)

Article Oncology

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

S. F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N. J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E. G. E. de Vries, M. Piccart, N. I. Cherny

Summary: This article discusses the importance of quality of life (QoL) data and quality assurance measures in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Through field testing and revision, a checklist consisting of four items was developed to ensure the reliability and clinical relevance of QoL data. Implementation of this checklist will facilitate objective and transparent decision making in the ESMO-MCBS scoring process.

ANNALS OF ONCOLOGY (2023)

Article Oncology

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER plus Breast Cancer Undergoing Treatment with Rintodestrant

Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt

Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.

CLINICAL CANCER RESEARCH (2023)

Review Oncology

Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors

Jahlisa S. Hooiveld-Noeken, Annemarie C. Eggen, Emoke Racz, Elisabeth G. E. de Vries, Anna K. L. Reyners, Mathilde Jalving

Summary: This systematic review explores the potential of immune checkpoint inhibitors (ICIs) in treating advanced non-melanoma skin cancer (NMSC), comparing their effectiveness with melanoma. The study shows that ICIs have comparable response rates in both advanced NMSC and melanoma, and neoadjuvant ICIs have shown promising results in NMSC, with approximately half of the patients achieving complete responses. The authors conclude that neoadjuvant ICI treatment has the potential to avoid mutilating treatments in NMSC, and further progress can be made by learning from melanoma.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Article Biochemistry & Molecular Biology

Whole-body CDS+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Laura Kist de Ruijter, Pim P. van de Donk, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Sjoerd G. Elias, Marjolijn N. Lub-de Hooge, Sjoukje F. Oosting, Mathilde Jalving, Wim Timens, Adrienne H. Brouwers, Thomas C. Kwee, Jourik A. Gietema, Rudolf S. N. Fehrmann, Bernard M. Fine, Sandra M. Sanabria Bohorquez, Mahesh Yadav, Hartmut Koeppen, Jing Jing, Sebastian Guelman, Mark T. Lin, Michael J. Mamounas, Jeffrey Ryan Eastham, Patrick K. Kimes, Simon P. Williams, Alexander Ungewickell, Derk J. A. de Groot, Elisabeth G. E. de Vries

Summary: Immune checkpoint inhibitors (ICIs), by reinvigorating CD8(+) T cell mediated immunity, have revolutionized cancer therapy. However, the systemic distribution and pharmacodynamics of CD8(+) T cells in response to ICIs remains poorly understood. In this study, we used a zirconium-89-labeled, CD8-specific antibody PET tracer to characterize the dynamic distribution of CD8(+) T cells in patients with solid tumors before and after ICI therapy. The results revealed significant heterogeneity in CD8(+) T cell distribution and pharmacodynamics both between and within patients.

NATURE MEDICINE (2022)

Article Oncology

Changes in survival in de novo metastatic cancer in an era of new medicines

Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H. J. T. de Hingh, Frank J. P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G. E. de Vries, Carin A. Uyl-de Groot, Sabine Siesling

Summary: This study evaluated the changes in survival of patients with de novo metastatic solid cancers over the past 30 years. The proportion of M1 disease and net survival rates varied among different cancer types. Better preventive measures and early detection are needed to reduce the incidence of metastatic disease.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Editorial Material Multidisciplinary Sciences

Towards evidence-based response criteria for cancer immunotherapy

Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G. E. de Vries

Summary: Early detection of immunotherapy-induced tumor response is crucial, but therapy-induced pseudoprogression can make it complicated. A consensus guideline called iRECIST, a modification of RECIST version 1.1, was developed. This article explores the next steps required to test its validity and proposes novel approaches for response criteria.

NATURE COMMUNICATIONS (2023)

Article Oncology

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale

Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.

CANCER MEDICINE (2023)

Article Oncology

Cancer Medicines: What Is Essential and Affordable in India?

Manju Sengar, Adam Fundytus, Wilma Hopman, C. S. Pramesh, Venkatraman Radhakrishnan, Prasanth Ganesan, Aju Mathew, Dorothy Lombe, Matthew Jalink, Bishal Gyawali, Dario Trapani, Felipe Roitberg, Elisabeth G. E. De Vries, Lorenzo Moja, Andre Ilbawi, Richard Sullivan, Christopher M. Booth

Summary: This study evaluated the highest priority drugs identified by Indian oncologists and their availability in routine practice. The results showed that the most commonly selected drugs were conventional cytotoxic drugs, but access to these treatments was limited by significant financial burdens experienced by patients, especially within the private health system.

JCO GLOBAL ONCOLOGY (2022)

No Data Available